|
rs150801101
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs151305324
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs1529909
|
|
|
0.010 |
GeneticVariation |
BEFREE |
101 hypertensive patients with hyperuricemia were detected the genotypes of URAT1 rs1529909 and rs3825016 and undergo a 2-weeks following losartan treatment.
|
26086348 |
2015 |
|
rs1555206402
|
|
A |
0.700 |
CausalMutation |
CLINVAR |
|
|
|
|
rs1653624
|
|
|
0.010 |
GeneticVariation |
BEFREE |
IL-1β concentrations in supernatants after MSU + ATP stimulation were significantly higher in gouty patients than in the hyperuricemia group [(131.08 ± 176.11) pg/ml vs. (50.84 ± 86.10) pg/ml]; Patients (including gout and hyperuricemia) carrying the susceptibility genotype AA or AT of rs1653624 exhibited significantly higher concentrations of IL-1β than patients carrying the non-susceptibility genotype TT [(104.20 ± 164.25) pg/ml vs. (21.90 ± 12.14) pg/ml]; However, no differences were found with MSU stimulation alone.
|
28797095 |
2017 |
|
rs16890979
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years.
|
29879316 |
2018 |
|
rs1800562
|
|
|
0.010 |
GeneticVariation |
BEFREE |
The increase in uricemia is associated with the increase in ferritin in a population of patients who were homozygous for the HFE gene mutation p.Cys282Tyr and this independently of factors commonly associated with hyperuricemia.
|
27659401 |
2017 |
|
rs1822825
|
|
|
0.010 |
GeneticVariation |
BEFREE |
BMI, gender, and the rs1822</span>825 polymorphism in the PPARγ gene appeared good biomarkers in hyperuricemia; therefore, these powerful indicators may be included in the prediction of hyperuricemia</span> to increase the accuracy of the analysis.
|
23237621 |
2013 |
|
rs186459505
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs187238
|
|
|
0.010 |
GeneticVariation |
BEFREE |
For the Kazak population, only IL-18 rs187238 showed statistical significance with hyperuricemia (P=0.002 by genotype and P=0.007, OR 1.823 by allele).
|
26722554 |
2015 |
|
rs189660050
|
|
|
0.010 |
GeneticVariation |
BEFREE |
ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia.
|
21594610 |
2011 |
|
rs199897813
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs200469773
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs200548390
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs200933617
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs201178535
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs201874364
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs202007714
|
|
|
0.700 |
GeneticVariation |
GWASCAT |
Identification of CDC42BPG as a novel susceptibility locus for hyperuricemia in a Japanese population.
|
29124443 |
2018 |
|
rs2054576
|
|
|
0.010 |
GeneticVariation |
BEFREE |
We identified a hyperuricemia susceptible loci (rs2054576 in ABCG2, OR, 1.883; P = 4.7 × 10⁻⁸) that passed a genome-wide significance threshold, adjusted by clinical variables (male, age, BMI, current alcohol, and creatinine).
|
28776340 |
2017 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)).
|
23238572 |
2013 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The rs2231142 allele G was the protective factor in Uygur hyperuricemia patients.
|
30197413 |
2018 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Previous studies have suggested an association between hyperuricemia and gout susceptibility relative to dysfunctional ABCG2 variants, with rs2231142 (Q141K) being the most common.
|
30894219 |
2019 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Whereas the rs2231142 in ABCG2 gene had significant associations between gout and controls, between gout and hyperuricemia, and between hyperuricemia and controls (all p-values < 10<sup>-7</sup>), and the ORs were 4.34, 3.37 and 2.15 (all p-values < 0.001) after adjustment of potential confounders, respectively.
|
29453348 |
2018 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
The rs2231142 SNP is associated with serum UA levels and hyperuricemia in Taiwanese patients and it occurs predominantly in male or obese patients.
|
26792383 |
2017 |
|
rs2231142
|
|
|
0.800 |
GeneticVariation |
BEFREE |
Finally, we have demonstrated the utility of using small molecules to correct the Q141K defect in expression and function as a possible therapeutic approach for hyperuricemia and gout.
|
23493553 |
2013 |